林业发展局批准Spravato鼻腔喷雾作为抗治疗性抑郁症的独立治疗方法。 FDA approves Spravato nasal spray as standalone treatment for treatment-resistant depression.

林业发展局批准了Johnson & Johnson的鼻鼻喷喷剂Spravato,作为针对患有严重抑郁症的成年人的独立治疗,这些成年人至少对另外两种抗抑郁药没有反应。 The FDA has approved Johnson & Johnson's nasal spray, Spravato, as a standalone treatment for adults with major depressive disorder who have not responded to at least two other antidepressants. 这是第一次针对抗治疗性抑郁症的独立治疗。 This is the first such standalone treatment for treatment-resistant depression. Spravato最初于2019年核准用于口服抗抑郁药,现在显示,Spravato在24小时内自行提供显著的症状缓解,无需每日口服口服药品。 Approved initially in 2019 for use with oral antidepressants, Spravato is now shown to provide significant symptom relief within 24 hours on its own, without daily oral medication. 这种药物源自氯胺酮,由于潜在的严重副作用,必须在经过认证的医疗保健环境中加以管理。 The drug, derived from ketamine, must be administered in certified healthcare settings due to potential serious side effects. 美国有2 000多万成年人患有严重的抑郁症,约有三分之一的成年人仅对口服抗抑郁药物没有反应。 Over 20 million adults in the U.S. have major depressive disorder, with about one-third not responding to oral antidepressants alone.